Kill-kinetic methods were used to provide data on the bactericidal activity of subinhibitory (0.5x MIC), inhibitory (ix MIC), and suprainhibitory (4x MIC) concentrations of LY146032 against methicillinsusceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. These bactericidal activities were compared with those of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin. LY146032 was among the most active of the antistaphylococcal agents tested, as determined by broth microdilution methods, with all strains being inhibited at concentrations of '1 ,ug/ml. Time kill-kinetic studies demonstrated that at 4x MIC, LY146032 was rapidly bactericidal against all strains of staphylococci. Our data show that LY146032 has significant bactericidal activity against staphylococci in comparison with other antistaphylococcal agents. Further evaluation of LY146032 against serious staphylococcal infections is warranted.
LY146032 is a cyclic polypeptide which has been shown by standard broth dilution techniques to be bactericidal against staphylococci at concentrations near the MIC (6-8, 14, 25) . This suggests that LY146032 may be useful clinically as a single agent against serious staphylococcal infectons, including endocarditis. To provide additional data on the bactericidal activity of LY146032 in comparison with those of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin, kill-kinetic methods were used in this study to compare the subinhibitory (0.5x MIC), inhibitory (lx MIC), and suprainhibitory (4x MIC) concentrations of these agents.
MATERIALS AND METHODS
Microorganisms. One hundred isolates of staphylococci obtained from blood were studied. Included in these isolates were 25 strains of methicillin-susceptible (MIC, .2 jig/ml) S. aureus, 25 strains of methicillin-resistant (MIC, -16 ptg/ml) S. aureus, 25 strains of methicillin-susceptible (MIC, .2 ,ug/ml) S. epidermidis, and 25 strains of methicillin-resistant (MIC, . 16 ,ug/ml) S. epidermidis. Identification of S. aureus was performed by a previously established methodology (13) which included colony morphology, Gram stain characteristics, ability to coagulate rabbit serum, and the presence of heat-stable DNase activity. Identification of S. epidermidis was done by using criteria and methods established by Kloos and Jorgensen (13) . Methicillin-susceptible and -resistant strains were determined by a reference broth microdilution method with Mueller-Hinton broth containing 2% NaCl (20, 24) . S. aureus ATCC 29213 was included for quality control in all susceptibility test procedures.
Antimicrobial agents. Antimicrobial agents most likely to be used in a clinical situation involving staphylococci were selected. Standard powders were obtained from the following sources: LY146032, cefazolin, cefamandole, and vancomycin, Eli Lilly & Co., Indianapolis, Ind., methicillin, Beecham Laboratories, Bristol, Tenn.; cefuroxime, Glaxo Research Laboratories, Research Triangle Park, N.C.; and * Corresponding author. ciprofloxacin, Miles Pharmaceuticals, West Haven, Conn. Antimicrobial stock solutions were prepared according to the instructions of the manufacturers and stored at -70°C until use. Final concentrations were prepared on the day they were used.
Media. Mueller-Hinton broth (BBL Microbiology Systems, Cockeysville, Md.) was used in both the broth microdilution method and the kill-kinetic method and was supplemented with 2% NaCl for the testing of beta-lactam agents (20, 24) and with physiologic concentrations of calcium and magnesium for the testing of LY146032 (6, 7) . Physiologic concentrations of calcium and magnesium were achieved by using a final concentration of 50 mg of Ca2+ and 25 mg of Mg2+ per liter of medium.
Inoculum. A sterile swab was used to remove >100 colonies from a plate culture; these colonies were then inoculated into Trypticase soy broth (BBL) and incubated. The turbidity of the logarithmic-phase culture was adjusted to a 0.5 McFarland standard by using tryptic soy broth. Further dilutions were done as determined by the specific susceptibility test method by using cation-supplemented Mueller-Hinton broth. The inoculum used was carefully controlled, and the final concentration was confirmed by a modified surface colony count method (19) . For this method, 10-fold dilutions were made in physiologic saline, and a calibrated micropipette was used to deliver five 0.05-ml samples from each dilution onto a sheep blood agar plate. These plates were incubated for 24 h, colonies were counted and averaged, and the final inoculum was calculated.
Broth microdilution method. The broth microdilution was done as described by the National Committee for Clinical Laboratory Standards (20) In Tables 8, 9 , and 10 is indicated the bactericidal effect against methicillin-susceptible S. epidermidis for each antibiotic at 0.5x, lx, and 4x MICs, respectively. LY146032 was among the most bactericidal agents of those tested, but was less bactericidal at lower concentrations (0.5x and 1x MICs) against methicillin-susceptible S. epidermidis than against methicillin-susceptible S. aureus. Ciprofloxacin was less bactericidal at lower concentrations against methicillinsusceptible S. epidermidis than against methicillinsusceptible S. aureus. Vancomycin was more bactericidal against methicillin-susceptible S. epidermidis than it was against methicillin-susceptible S. aureus. Regrowth of methicillin-susceptible S. epidermidis was rarely seen at the 4x MIC of vancomycin. Bactericidal activities of the betalactam agents against methicillin-susceptible S. epidermidis were similar to those against methicillin-susceptible S. aureus, with the exception of cefuroxime, which was less bactericidal than the other agents tested. Cefazolin and cefamandole were the most bactericidal of the beta-lactam agents tested against methicillin-susceptible S. epidermidis.
In Tables 11, 12 , and 13 is indicated the bactericidal effect against methicillin-resistant S. epidermidis for each antibiotic at 0.5x, lx, and 4x MICs, respectively. LY146032 was rapidly bactericidal against methicillin-resistant S. epidermidis. Vancomycin was even more rapidly bactericidal against methicillin-resistant S. epidermidis. Ciprofloxacin was less bactericidal against methicillin-resistant S. epidermidis than against methicillin-resistant S. aureus. Cefamandole was the most active beta-lactam agent of those tested against (2, 16, 17, 22) . Moreover, methicillin-resistant isolates are being seen with increasing frequency and often necessitate treatment with vancomycin (1, 23) . LY146032 is a recently developed antibiotic (6, 7) which belongs to a novel class of acidic lipopeptide agents (6) . This cell wall-active agent has demonstrated significant in vitro activity against staphylococci, with bactericidal activity being near the MIC (6-8, 14, 25) . This study was undertaken to provide additional data on the bactericidal activity of LY146032 in comparison with the activity of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin. Kill-kinetic studies were done to compare the 0.5x, lx, and 4x MICs of these agents. Cell wall-active agents with recognized activity against staphylococci were studied. Ciprofloxacin, a noncell-wall-active agent, was included because of its in vitro activity against S. aureus (3, 9, 12). The Mueller-Hinton broth was supplemented with 2% NaCl (20, 25) and with calcium and magnesium; the latter cation supplementation was done because the in vitro activity of the acidic lipopeptide agents (including that of LY146032) demonstrates a striking dependence on calcium concentration in the growth medium (6, 7) .
LY146032 and ciprofloxacin were the most active agents, as determined by broth microdilution methods, with all strains of staphylococci being inhibited at concentrations of <1 p.g/ml. Vancomycin also was quite active against all strains, with MICs of <2 ,ug/ml. Results of kill-kinetic studies demonstrated that LY146032 was rapidly bactericidal against methicillin-susceptible S. aureus. LY146032 was not as rapidly bactericidal against methicillin-resistant S. aureus as it was against methicillin-susceptible S. aureus, possibly because of the tendency for methicillin-susceptible S. aureus to grow more slowly (21) . At 4x MICs vancomycin was slowly bactericidal against methicillin-susceptible S. aureus and methicillin-resistant S. aureus; regrowth was seen at this concentration. Regrowth of methicillin-resistant S. aureus in the presence of vancomycin has been reported previously (9) . At all concentrations vancomycin was more rapidly bactericidal against S. epidermidis than it was against S. aureus. Although ciprofloxacin MICs were similar to those of LY146032, with a range of 0.125 to 1 ,ug/ml, ciprofloxacin demonstrated less bactericidal activity. This has been noted by others (9) . As expected, methicillin was bactericidal only to methicillin-susceptible S. aureus and methicillin-susceptible S. epidermidis. Of the cephalosporins tested, cefamandole had considerable bactericidal activity against both methicillin-resistant S. aureus and methicillinresistant S. epidermidis. This too has been noted previously (10) . The clinical importance of this in vitro activity is unclear. In many clinical studies failures have been reported when cephalosporins have been used to treat infections caused by methicillin-resistant staphylococci (1, 4) . This has led to the recommendation that vancomycin be used as the agent of choice for these infections. Yet, in some studies (11) cefamandole has been found to be effective clinically for a wide range of infections (excluding endocarditis) caused by methicillin-resistant staphylococci. Our data support the results of the latter studies, although cross-resistance between methicillin and cephalosporin agents with staphylococci (1, 18) 
